DS
- Product Details
- Reviews & Citations
No data
Cardiac organoids are three-dimensional in vitro models with a cellular composition and structural organization that is representative of the human heart. Human iPSC-Derived Cardiac Organoids are differentiated from human iPSCs using Human iPSC-Derived Cardiac Organoid Differentiation Kit. Differentiation was carried out by forming EBs from PSC at an ultra-low attachment interface, and then changing the medium according to the instructions. A spontaneously beating cardiac organoid with a cavity can be seen between days 9 and 13 of the onset of differentiation. Cardiomyocytes, key cellular component of cardiac organoid, are responsible for the beating of the cardiac organoids. The beating rate of the formed cardiac organoids increases dramatically when stimulated with isoproterenol or forskolin, and there is a linear relationship between the concentration of the drug and the beating rate over a range of concentrations. The organoid will be QC in day 18, and we start to send out from day 22. It's suggested to finish all the experiments before day 45. During transport, the organoids are kept in a low metabolic near resting state, and the timing restarts after the completion of the resuscitation step.
The live organoids are ready-to-use organoids that are delivered in shipping medium and has to go through a 48h recovery process according to instruction. The recovery process will use the maintenance medium (Cat. RIPO-HWM004).
After recovery, please store the organoid in its maintenance medium under the correct incubation condition and medium changing process.